Novo Medi Sciences Private Limited

Enoxaparin sodium is an anticoagulant medication commonly used to prevent and treat thromboembolic disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a low molecular weight heparin (LMWH) that works by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin), thereby reducing the formation of blood clots.

Key Characteristics:

• Administration: Enoxaparin is usually given via subcutaneous injection.
• Dosage Forms: It is available in pre-filled syringes and vials.
• Indications:
  • Prevention of DVT in patients undergoing surgery or those with restricted mobility.
  • Treatment of DVT and PE in conjunction with warfarin.
  • Prevention of thrombus formation in patients with unstable angina and non-ST elevation myocardial infarction (NSTEMI).

Mechanism of Action:

Enoxaparin enhances the activity of antithrombin III, leading to the inactivation of factor Xa and thrombin, which are crucial for the coagulation cascade.

Side Effects:

Common side effects may include:

• Bleeding
• Injection site reactions (pain, bruising)
• Thrombocytopenia (low platelet count)

Monitoring:

Routine monitoring of coagulation parameters is generally not required, but renal function and platelet counts should be monitored in certain populations, particularly in those with renal impairment.

Contraindications:

• Active major bleeding
• History of heparin-induced thrombocytopenia
• Severe renal impairment (with caution)